Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

September 27, 2024

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

September 14, 2024

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

September 07, 2024

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

September 04, 2024

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

August 26, 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

August 23, 2024

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

August 22, 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

August 21, 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

August 19, 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

August 19, 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

August 16, 2024

Investigators are developing preventive interventions to identify patients most at risk for financial toxicity and offer them assistance.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

August 12, 2024

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

August 07, 2024

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

July 31, 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.